Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamases

Gutmann, Laurent; Kitzis, M; Yamabe, Shigeru; Acar, J. F.

doi:10.1128/aac.29.5.955

Cited by 105 publications

(58 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, since PSE-1 is still most prevalent in P. aeruginosa and is only rarely found in members of the Enterobacteriaceae, all of the studies concerning the effects of potassium clavulanate on strains possessing this enzyme specifically have been performed in P. aeruginosa. Such studies have shown that MICs or MBCs of penicillins for P. aeruginosa with PSE-1 may be reduced by potassium clavulanate; however, they usually do not fall into the clinically achievable range (3,6).…”

Section: Discussionmentioning

confidence: 99%

Resistance to ticarcillin-potassium clavulanate among clinical isolates of the family Enterobacteriaceae: role of PSE-1 beta-lactamase and high levels of TEM-1 and SHV-1 and problems with false susceptibility in disk diffusion tests

Sanders

Iaconis

Bodey

et al. 1988

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Thirty-four clinical isolates of the family Enterobacteriaceae from the University of Texas M. D. Anderson Cancer Center appeared resistant to ticarcillin-potassium clavulanate in agar dilution and broth macrodilution tests. Among those isolates producing a single non-class I beta-lactamase, resistance was due to production of high levels of TEM-1, SHV-1, or class IV enzymes. In five Escherichia coli isolates, production of low levels of PSE-1 was responsible for resistance which seemed due to rapid hydrolysis of ticarcillin rather than diminished susceptibility of PSE-1 to inhibition by potassium clavulanate. Comparisons of dilution and disk diffusion tests revealed major discrepancies, with 65% false susceptibility in the disk test. Revision of the interpretive criteria used for disk diffusion tests from less than or equal to 11 to less than or equal to 18 mm for resistance is proposed to resolve these discrepancies until clinical data are obtained which can be used to determine which in vitro test is most predictive of therapeutic outcome. These new criteria would diminish false susceptibility without introducing false resistance.

show abstract

Section: Discussionmentioning

confidence: 99%

Resistance to ticarcillin-potassium clavulanate among clinical isolates of the family Enterobacteriaceae: role of PSE-1 beta-lactamase and high levels of TEM-1 and SHV-1 and problems with false susceptibility in disk diffusion tests

Sanders

Iaconis

Bodey

et al. 1988

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…The com bina tion of ta zo bac tam with peni cil lins and broad spec trum cepha lo sporins has dem on strated broad an ti mi cro bial ac tiv ity (19,20).…”

Section: T He Introduction Of Third-generation Cephalo-mentioning

confidence: 99%

“…Ta zo bac tam is a re cently stud ied peni cil lanic acid sul fone that in hib its a wide va ri ety of lac ta mases (17)(18)(19)(20)(21). The com bina tion of ta zo bac tam with peni cil lins and broad spec trum cepha lo sporins has dem on strated broad an ti mi cro bial ac tiv ity (19,20).…”

Section: T He Introduction Of Third-generation Cephalo-mentioning

confidence: 99%

Comparative Activity of Several Antimicrobial Agents against Nosocomial Gram‐Negative Rods Isolated across Canada

Scriver

Low²

1994

Canadian Journal of Infectious Diseases and Medical Microbiolog

View full text Add to dashboard Cite

SR SCRIVER, CANA DIAN ANTI MI CRO BIAL RESIS TANCE STUDY GROUP, DE LOW.Com para tive ac tiv ity of sev eral an ti mi crobial agents against no so comial Gram-negative rods iso lated across Can ada. Can J In fect Dis 1995;6(2):76-82. In 1992, a sur veil lance study was per formed in Can ada to de ter mine the sus cep ti bil ity of no so comial Gram-negative rods to sev eral wide spec trum an ti mi cro bi als. Con secu tive iso lates from 10 in sti tu tions, as well as ad di tional strains of se lected spe cies of En tero bac te riaceae that are known to pos sess the Bush group 1 beta-lactamase, were tested for sus cep ti bil ity to 12 an ti mi cro bi als. Third-generation cepha lo sporin re sis tance was found to be as high as 29% in En terobac ter cloa cae that pos sesses the Bush group 1 beta-lactamase and less than 4% in those iso lates not pos sess ing this en zyme. Ce fepime equalled or ex ceeded the ac tiv ity of the third-generation cepha lo sporins against the spe cies of Entero bac te riaceae that dem on strated re sis tance to the third-generation cepha lo sporins. Key Words: An ti mi cro bial re sis tance, Gram-negative rods Activité comparative de plusieurs antibiotiques contre les souches nosocomiales gram-négatives isolées au CanadaRÉS UMÉ : En 1992, une étude épidémi olo gique a été ef fec tuée au Can ada afin de dé ter mi ner le de gré de sen si bil ité des souches noso comia les Gram-négatives à di vers anti bio tiques à large spec tre. Des iso lats consé cu tifs prove nant de dix établis se ments, de même que d'autres souches d'e spèces sé lec tionnées d'En tero bac te riaceae dont on sait qu'elles sont do tées de bêta-lactamases Bush de groupe 1 ont été sou mis à des épreu ves de sen si bil ité à 12 an ti mi crobiens. Une résis tance de l'or dre de 29 % aux cépha lo spor ines de troisième gé né ra tion a été ob servée dans une souche d'En tero bac ter cloa cae do tée de bêta-lactamases Bush du groupe 1, et infé rieure à 4 % dans les iso lats dépour vus de cet en zyme. La céfépime a mani festé une ac tiv ité égale ou supé rieure aux cépha lo spor ines de troisième gé né ra tion con tre les espèces d'En tero bac te riaceae qui mani fes taient une résis tance aux cépha lo spor ines de troisième gé né ration. 76CAN J INFECT DIS VOL 6 NO 2 MARCH/APRIL 1995

show abstract

“…In particular, tazobactam is a better inhibitor of the chromosomal cephalosporinases of members of the family Enterobactenaceae (Enterobacter, Serratia, and Citrobacter spp.) than are sulbactam and clavulanic acid (8,10). However, this difference might not be clinically significant.…”

mentioning

confidence: 99%

“…Piperacillin is a broadspectrum penicillin which has a high level of in vitro activity against members of the family Enterobacteriaceae and Pseudomonas aeruginosa. Tazobactam is an effective inhibitor of various types of 3-lactamases, especially the penicillinase type of Staphylococcus aureus, the TEM types, and the cephalosporinase of Bacteroides fragilis (2,3,(8)(9)(10)14). In particular, tazobactam is a better inhibitor of the chromosomal cephalosporinases of members of the family Enterobactenaceae (Enterobacter, Serratia, and Citrobacter spp.)…”

mentioning

confidence: 99%

Ex vivo pharmacodynamic study of piperacillin alone and in combination with tazobactam, compared with ticarcillin plus clavulanic acid

Auwera

Duchateau

Lambert

et al. 1993

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Ten volunteers received piperacillin (4 g), piperacillin (4 g) plus tazobactam (0.5 g) (Tazocin), and ticarcillin (3 g) plus clavulanic acid (0.2 g) (Timentin) intravenously over 30 min in a cross-over blinded scheme. Blood samples were obtained 0.5 and 3 h after the end of infusion to measure by (high-pressure liquid chromatography) the concentration and bactericidal titers against 70 gram-negative bacilli. Serum time-kill curves were done against 35 strains to measure killing rates and area under the time-kill curve. Using the measure of serum bactericidal activity, ticarcillin-clavulanic acid and piperacillin-tazobactam were equally effective against Pseudomonas aeruginosa, Escherichia coli, Enterobacter cloacae, Serratia marcescens, and Bacteroidesfragilis. Piperacillin-tazobactam was superior to ticarcillin-clavulanic acid against piperacillin-resistant Kiebsiella pneumoniae (4 to 16 times) and S. marcescens (2 to 4 times). By using the area under the time-kill curve, piperacillin-tazobactam was equivalent to ticarcillin-clavulanic acid against piperacillin-susceptible strains; piperacillin-tazobactam was significantly more active than piperacillin against piperacillin-resistant strains and was more active than ticarcillin-clavulanic acid when the sample obtained 3 h after the end of infusion to volunteers was considered. Serum piperacillin concentrations (mean standard error of the mean; in mg/liter) were 115 + 13 at 0.5 h and 7.4 + 1.4 at 3 h after the administration of piperacillin alone and 105.5 12.6 (0.5 h) and 7.7 + 1.6 after the administration of piperacillin-tazobactam. Serum tazobactam concentrations (in milligrams per liter) were 13.1 1.4 at 0.5 h and 1.2 + 0.2 at 3 h. The piperacillin-tazobactam ratio was 8 0.3 at 0.5 h and 6.2 0.5 at 3 h. Piperacillin-tazobactam appears promising against ,3-lactamase-producing gram-negative bacilli.Infections by gram-negative organisms are still a major cause of morbidity in patients with cancer, especially when they are neutropenic (19). Treatment of these infections often consists of the administration of a broad-spectrum ,-lactam antibiotic in combination with an aminoglycoside, although the use of monotherapy with a broad-spectrum cephalosporin or imipenem has been advocated. The increasing incidence of gram-negative bacilli with broad-spectrum ,3-lactamases has caused the empiric use of monotherapy to be questioned. One way to overcome this problem is use of the combination of a broad-spectrum penicillin with an effective ,-lactamase inhibitor. Piperacillin is a broadspectrum penicillin which has a high level of in vitro activity against members of the family Enterobacteriaceae and Pseudomonas aeruginosa. Tazobactam is an effective inhibitor of various types of 3-lactamases, especially the penicillinase type of Staphylococcus aureus, the TEM types, and the cephalosporinase of Bacteroides fragilis (2,3,(8)(9)(10)14). In particular, tazobactam is a better inhibitor of the chromosomal cephalosporinases of members of the family Enterobactenaceae (Enterobacter,...

show abstract

Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamases

Cited by 105 publications

References 7 publications

Resistance to ticarcillin-potassium clavulanate among clinical isolates of the family Enterobacteriaceae: role of PSE-1 beta-lactamase and high levels of TEM-1 and SHV-1 and problems with false susceptibility in disk diffusion tests

Resistance to ticarcillin-potassium clavulanate among clinical isolates of the family Enterobacteriaceae: role of PSE-1 beta-lactamase and high levels of TEM-1 and SHV-1 and problems with false susceptibility in disk diffusion tests

Comparative Activity of Several Antimicrobial Agents against Nosocomial Gram‐Negative Rods Isolated across Canada

Ex vivo pharmacodynamic study of piperacillin alone and in combination with tazobactam, compared with ticarcillin plus clavulanic acid

Contact Info

Product

Resources

About